BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Engagement of Tailwinds Research Group, Video Update and Strategic Advisory Board Appointment

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced its engagement of Tailwinds Research Group to provide digital content distribution for the company. According to the update, the engagement will cover a 1-year term, at US$2,500/month with 100,000 stock options provided at C$0.88/option. In addition, LexaGene today released a video message from its founder and CEO, Dr. Jack Regan, that highlighted the company’s progress toward commercial sales and announced the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. “As we approach sales, I’m very pleased to add Dr. Rankin to our Scientific Advisory Board,” said Dr. Regan of the appointment. “She is an outspoken key opinion leader in veterinary medicine and is constantly advocating for high quality diagnostics for veterinarians in order to promote better animal health and antibiotic stewardship. We look forward to working with her to help meet the needs of veterinarians worldwide.”

To view the full press releases, visit https://ibn.fm/xZQYx and https://ibn.fm/itMfk

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The MiQLab analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time “PCR” assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork